Novel Drug for HER2-Mutant Lung Cancer Wins FDA Approval

(MedPage Today) — The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain (TKD) activating mutations.
Approval of the tyrosine…

Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116921

Author :

Publish date : 2025-08-08 21:19:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Novel Drug for HER2-Mutant Lung Cancer Wins FDA Approval

A planet the size of Saturn could orbit the nearest Sun-like star

FDA Approves Zongertinib for HER2-Mutated NSCLC

Related Posts

Old Organ Transplant Drug Delayed Beta-Cell Loss in Type 1 Diabetes

What Is BMD’s Impact as a Surrogate Osteoporosis Endpoint?

CDC Panel Stops Endorsing COVID Shots, Pushes for ‘Choice’

WHO Says 31 of 38 Ebola Cases in Congo Have Resulted in Deaths

A Dozen More Charged in Alleged Massive Nursing Diploma Scam

Full Scalp Hair Regrowth Possible With Oral JAK Inhibitor

Old Organ Transplant Drug Delayed Beta-Cell Loss in Type 1 Diabetes

What Is BMD’s Impact as a Surrogate Osteoporosis Endpoint?

CDC Panel Stops Endorsing COVID Shots, Pushes for ‘Choice’

WHO Says 31 of 38 Ebola Cases in Congo Have Resulted in Deaths

A Dozen More Charged in Alleged Massive Nursing Diploma Scam

Full Scalp Hair Regrowth Possible With Oral JAK Inhibitor

ACIP Is Now Obsolete. Here’s Where Medicine Can Look Instead.

Repurposed Drugs Show Promise in Preventing T1D Progression

Categories

Archives